Literature DB >> 18775021

Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy.

Frédérique Maire1, Hélène Voitot, Alain Aubert, Laurent Palazzo, Dermot O'Toole, Anne Couvelard, Philippe Levy, Michel Vidaud, Alain Sauvanet, Philippe Ruszniewski, Pascal Hammel.   

Abstract

INTRODUCTION: The preoperative diagnosis of intraductal papillary mucinous neoplasms (IPMN) of the pancreas must be as reliable as possible because large or even total pancreatectomy may be necessary. Early diagnosis of malignant forms is important to improve prognosis. The diagnostic accuracy of fluid analysis using endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has been confirmed in cystic lesions of the pancreas. It is not known if these results can be applied to IPMN. AIMS: To determine the levels of biochemical and tumor markers in fluid from EUS-FNA in patients with IPMN and to assess the impact on the diagnosis of IPMN. PATIENTS AND METHODS: In total, 41 patients (14 men, median age 64 yr) underwent EUS-FNA before surgical resection of IPMN in our center. Levels of amylase, lipase, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19.9, and CA 72.4 were measured in the cyst fluid. The performance of the markers was retrospectively evaluated for: (a) a positive diagnosis of IPMN, using cutoffs validated in the literature for mucinous pancreatic lesions and (b) an assessment of malignancy (i.e., high-grade dysplasia or invasive carcinoma) compared with the final pathological examination of the surgical specimen.
RESULTS: EUS-FNA was performed in dilated branch ducts (BD) in 39 cases and in the main pancreatic duct in 2 cases. No serious complications occurred. The median fluid levels of amylase, lipase, CEA, CA 19.9, and CA 72.4 were 20,155 U/mL, 59,500 U/mL, 173 ng/mL, 6,400 U/mL, and 11.5 U/mL, respectively. A CEA level >200 ng/mL and a CA 72.4 >40 U/mL had a 44% and a 39% sensitivity, respectively, for the diagnosis of IPMN. The levels of CEA, CA 19.9, and CA 72.4 were significantly different between benign and malignant IPMN. The sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) of a CEA level >200 ng/mL for the diagnosis of malignant IPMN were 90%, 71%, 50%, and 96%, respectively. The sensitivity, specificity, PPV, and NPV of a CA 72.4 level >40 U/mL for this purpose were 87.5%, 73%, 47%, and 96%, respectively.
CONCLUSION: CEA and CA 72.4 in pancreatic cyst fluid have excellent NPVs in the preoperative differential diagnosis of benign versus malignant IPMN, and might reinforce the decision of not to operate on patients with BD-type without predictive factors of malignancy.

Entities:  

Mesh:

Year:  2008        PMID: 18775021     DOI: 10.1111/j.1572-0241.2008.02114.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  Pancreatic cystic lesions: How endoscopic ultrasound morphology and endoscopic ultrasound fine needle aspiration help unlock the diagnostic puzzle.

Authors:  Luca Barresi; Ilaria Tarantino; Antonino Granata; Gabriele Curcio; Mario Traina
Journal:  World J Gastrointest Endosc       Date:  2012-06-16

2.  Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia.

Authors:  Terry K Morgan; Karin Hardiman; Christopher L Corless; Sandra L White; Robert Bonnah; Henry Van de Vrugt; Brett C Sheppard; Markus Grompe; Ediz F Cosar; Philip R Streeter
Journal:  Cancer Cytopathol       Date:  2012-07-18       Impact factor: 5.284

3.  Routine Cyst Fluid Cytology Is Not Indicated in the Evaluation of Pancreatic Cystic Lesions.

Authors:  Lawrence A Shirley; Jon Walker; Somashekar Krishna; Samer El-Dika; Peter Muscarella; E Christopher Ellison; Carl R Schmidt; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2016-05-26       Impact factor: 3.452

Review 4.  Approach to cystic lesions of the pancreas.

Authors:  Roland M Schmid; Jens T Siveke
Journal:  Wien Med Wochenschr       Date:  2013-11-20

5.  Evaluation of cyst fluid CEA analysis in the diagnosis of mucinous cysts of the pancreas.

Authors:  Satish Nagula; Timothy Kennedy; Mark A Schattner; Murray F Brennan; Hans Gerdes; Arnold J Markowitz; Laura Tang; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2010-07-24       Impact factor: 3.452

Review 6.  Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.

Authors:  Robert Grützmann; Marco Niedergethmann; Christian Pilarsky; Günter Klöppel; Hans D Saeger
Journal:  Oncologist       Date:  2010-12-08

7.  Role of a multidisciplinary clinic in the management of patients with pancreatic cysts: a single-center cohort study.

Authors:  Anne Marie Lennon; Lindsey L Manos; Ralph H Hruban; Syed Z Ali; Elliot K Fishman; Ihab R Kamel; Siva P Raman; Atif Zaheer; Susan Hutfless; Ashley Salamone; Vandhana Kiswani; Nita Ahuja; Martin A Makary; Matthew J Weiss; Kenzo Hirose; Michael Goggins; Christopher L Wolfgang
Journal:  Ann Surg Oncol       Date:  2014-05-08       Impact factor: 5.344

Review 8.  The Role of Endoscopic Ultrasound in the Diagnosis of Cystic Lesions of the Pancreas.

Authors:  Philippe Lévy; Vinciane Rebours
Journal:  Visc Med       Date:  2018-06-08

9.  Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.

Authors:  Dirk Bausch; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Andrew L Warshaw; Kimberly A Kelly; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

Review 10.  [Differentiated therapy for intraductal papillary mucinous neoplasms].

Authors:  M N Wente; B M Schmied; J Schmidt; M W Büchler
Journal:  Chirurg       Date:  2009-01       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.